Аркадий Верткин - Коморбидный пациент. Руководство для практических врачей

17. Hoffman C, Rice D, Sung H. Y. Persons with chronic conditions: their prevalence and costs. JAMA 1996; 276:1473–1479.

18. Мировая статистика здравоохранения. ВОЗ, Женева, 2007.

19. Zitzmann et al. J Chin Endocrinol Metab. 2006 91: 4335–4343.

20. Linn B. S., Linn M. W., Gurel L. Cumulative illness rating scale // J Amer Geriatr Soc. – 1968. – V. 16. – Р. 622–626.

21. Miller M. D., Paradis C. F., Houck P. R., Mazumdar S., Stack J. A., Rifai A. H. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale // Psychiatry Res. – 1992. – V. 41. – Р. 237–48.

22. Miller M. D., Towers A. A. Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) // Pittsburg, Pa: University of Pittsburgh. – 1991.

23. Linn M. W. A rapid disability rating scale // J. Am. Geriat. Soc. – 1967. – V. 15. – P. 211.

24. Charlson M. E., Pompei P., Ales K. L. et al. A new method of classifying prognostic comorbidity in longitudinal studies development and validation // J Chron Dis. – 1987. – T. 40. – Р. 373–342.

25. Chien-Ying Wang, Yu-Sen Lin, Ching Tzao, Hui-Chen Lee at al. Comparison of Charlson comorbidity index and Kaplan – Feinstein index in patients with stage I lung cancer after surgical resection // Eur J Cardiothorac Surg. – 2007. – V. 32. – Р. 877–881.

26. Groot V., Beckerman H., Lankhorst G. J., Bouter L. M. How to measure comorbidity: a critical review of available methods // J Clin Epidemiol. – 2003. – Mar. – V. 56(3). – Р. 221–9.

27. Carey E. C., Walter L. C., Lindquist K., Covinsky K. E. Development and validation of a functional morbidity index to predict mortality in community-dwelling elders // J Gen Intern Med. – 2004. – Oct. V. 19(10). – Р. 1027–33.

28. Desai M. M., Bogardus S. T., Williams C. S., Vitagliano G., Inouye S. K. Development and validation of a risk-adjustment index for older patients: the high-risk diagnoses for the elderly scale // J Am Geriatr Soc. – 2002. – Mar. V. 50(3). – Р. 474–81.

29. Grolla D. L., Tob T., Bombardierc C., Wright J. G. The development of a comorbidity index with physical function as the outcome // Journal of Clinical Epidemiology. – 2005. – June, V. 58, I. 6. – Р. 595–602.

30. Rozzini R., Frisoni G. B., Ferrucci L., Barbisoni P., Sabatini T., Ranieri P., Guralnik J. M., Trabucchi M. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbidity // Age Ageing. – 2002. – Jul, V. 31(4). – Р. 277–85.

31. Walter L. C., Brand R. J., Counsell S. R., Palmer R. M., Landefeld C. S., Fortinsky R. H., Covinsky K. E. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization // JAMA. – 2001. – Junе, V. 285(23). – Р. 2987–94.

32. Sever P.S, Dahlöf B., Poulter N., Wedel H. et al, for the ASCOT Investigators. Lancet. 2003;361:1149–58.

33. Quillinan N. P., Denton C. P. Disease-modifying treatment in systemic sclerosis: current status. Current Opinion in Rheumatology. 2009;21(6):636–641.

34. Stevens A. L., Coresh J., Greene T., Levey A. S. Assessing N Engl J Med 2006; 354: 2473–83.

35. Rubinshtein R., Kuvin J. T., Soffl er M., Lennon R. J., Nelson R. E., Pumper G. M., Lerman L. O., Lerman . A Assessment of Endothelial Function by Peripheral Arterial Tonometry Predicts Cardiovascular Events Beyond the Framingham Risk Score. jACC 2009; Suppl.

36. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ, 1998, 317, 371–375.

37. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study Diabetes (EASD). Eur Heart J Suppl 2007; 9: С3–С74.

38. Friedman G. D., Klatsky A. L., Siegelaub A. B. Lung function and risk of myocardial nfarction and sudden cardiac death // N Engl J Med 1976; 294:1071–5.

39. Raisz L. G. Physiology and pathophysiology of bone remodeling // Clin Chem 1999; 45:1353–8.

40. Schunemann H. J., Dorn J., Grant B. J. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the // Buff alo Health Study. Chest 2000;118:656-64.

41. Черешнев В. А., Гусев Е. Ю., Юрченко Л. Н. Системное воспаление – миф или реальность? // Вестник российской академии наук, 2004, том 74, № 3. С. 219–227.

42. Agusti A. Systemic eff ects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should) // Proc Am Thorac Soc. 2007; 4:522–525.

43. Мухарлямов Н. М., Саттбеков Ж. С., Сучков В. В. Системная артериальная гипертензия у больных хроническими неспецифическими заболеваниями легких // Кардиология. 1974:12(34); 55–61.

44. Серебрякова В. И. Клинико-патологические особенности нейроэндокринной регуляции при сочетании артериальной гипертензии с лабильной и стабильной обструкции бронхов в возрастном и половом аспекте, коррекция выявленных нарушений. // Авт. дисс. д-ра. мед. наук. СПб:1998; 55.

45. Волков В. Г. Бронхиальная астма и артериальная гипертензия. // Тер. архив. 1985, т. 57. № 3, с. 53–54.

46. Серебрякова В. И. Исследование функции внешнего дыхания у больных бронхиальной астмой в сочетании с артериальной гипертензией. // Сб. научных трудов СПбГСГМИ «Достижения медицины – практическому здравоохранению», Л., 1990. С. 50–51.

47. Lind L. Circulating markers of infl ammation and atherosclerosis // Atherosclerosis, 2003; 169: 203–214.

48. Verma S., Li S. H., Badiwala M. V. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic eff ects of C-reactive protein // Circulation 2002; 105:1890–1896.

49. Zwaka T. P., Homback V., Torzewski J. C-reactive protein mediated low density lipoprotein update by macrophages: implications for atherosclerosis // Circulation 2001; 103:1194–1197.

50. Gan W. Q., Man S. F., Senthilselvan A. Association between chronic obstructive pulmonary disease and systemic infl ammation: a systematic review and a meta-analysis // Thorax 2004; 59: 574–580.

51. Franciosi L. G., Page C. P., Celli B. R. Markers of disease severity in chronic obstructive pulmonary disease // Pulm Pharmacol Ther. 2006; 19:189–199.

52. Garcia-Rio F., Miravitlles M., Soriano J. B. Systemic infl ammation in chronic obstructive pulmonary disease: a population-based study // Respir Res. 2010 May 25; 11:63.

53. Hurst J. R., Donaldson G. C., Perera W. R. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease // Am J Respir Crit Care Med. 2006; 174:867–874.